Nanotherapeutics in transplantation: How do we get to clinical implementation?

Leah Plumblee, Carl Atkinson, Dinesh Jaishankar, Evan Scott, Gregory T. Tietjen, Satish N. Nadig*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Patients undergoing organ transplantation transition from one life-altering issue (organ dysfunction) to a lifelong commitment—immunosuppression. Regimens of immunosuppressive agents (ISAs) come with significant side effects and comorbidities. Recently, the use of nanoparticles (NPs) as a solution to the problems associated with the long-term and systemic use of ISAs in transplantation has emerged. This minireview describes the role of NPs in organ transplantation and discusses obstacles to clinical implementation and pathways to clinical translation.

Original languageEnglish (US)
Pages (from-to)1293-1298
Number of pages6
JournalAmerican Journal of Transplantation
Issue number5
StatePublished - May 2022


  • basic (laboratory) research/science
  • bioengineering
  • graft survival
  • immunosuppressant
  • immunosuppression/immune modulation
  • organ perfusion and preservation
  • organ transplantation in general
  • solid organ transplantation
  • translational research/science

ASJC Scopus subject areas

  • Transplantation
  • Pharmacology (medical)
  • Immunology and Allergy


Dive into the research topics of 'Nanotherapeutics in transplantation: How do we get to clinical implementation?'. Together they form a unique fingerprint.

Cite this